Biotech Values

[Whalatane]

ESPR. data release today ..

.http://investor.esperion.com/news-releases/news-release-details/esperion-announces-late-breaking-oral-presentation-final-results ESC

key pt.
— Bempedoic Acid Achieved Additional 20% On-Treatment LDL-C Lowering on Background of Maximally Tolerated Statins —

IMHO I think MDGL ( MDG-3196 ? ) might do better

Note
Design of Global Pivotal Phase 3 Study 1 (1002-040)

The 52-week, global, pivotal Phase 3 randomized, double-blind, placebo-controlled, multicenter study evaluated the long-term safety and tolerability of bempedoic acid 180 mg/day versus placebo in high-risk patients with ASCVD and/or heterozygous familial hypercholesterolemia (HeFH) with LDL-C levels of at least 70 mg/dL (1.8 mmol/L) who are inadequately controlled with current lipid-modifying therapies, including maximally tolerated statin therapy

Would need to chk MDGL's data but believe in same patients MGL-3196 lowered LDL by 28%

Kiwi